The Jenex Corporation replaces previously announced incentive stock
BURLINGTON, ON, Sept. 12 /CNW/ - The Jenex Corporation ("Jenex" or the
"Corporation") (TSX Venture Exchange: JEN, Frankfurt: JNX) announced today
that the corporation has agreed to grant 2,750,000 incentive stock options to
Directors, Officers, Employees and Consultants of the corporation, exercisable
at a price of thirty-five cents ($0.35) per share. Whereas, 2,400,000
incentive stock options are for a three year term ending September 12, 2010
and 350,000 incentive stock options are for a two year term ending
September 12, 2009. Option specifics are governed by the TSX-V requirements.
The transaction is subject to customary TSX Venture Exchange approval and
options shall be subject to a four month hold period. The granting of these
incentive stock options replaces the incentive stock options previously
announced in a press release dated May 25, 2007.
About The Jenex Corporation
The Jenex Corporation owns a patented Thermal Therapy technology. The
first device developed from this technology is the Therapik(R) product, for
relief of pain and itch caused by insect stings and bites. Therapik(R) has
been approved as a Class II medical device in Canada (TPD) and the United
States (FDA), and has received CE approval in Europe. The second device,
interceptCS is the first product clinically proven and approved (TPD) to
prevent cold sores . interceptCS is available exclusively in Canada at
Shoppers Drug Mart/Pharmaprix. More information about the Corporation can be
found at www.jenexcorp.com and www.interceptCS.com.
"Prevention is the Solution"
The TSX Venture Exchange Inc. has not reviewed and does not accept
responsibility for the accuracy or the contents of this press release.
For further information:
For further information: Direct Inquiries to: The Jenex Corporation, 207
- 940 Sheldon Court, Burlington, Ontario, L7L 5K6, Michael A. Jenkins,
Telephone: (905) 632-3830, Facsimile: (905) 632-3774, Email:
email@example.com, Website: www.jenexcorp.com